Veloxis Pharmaceuticals (OTC: VXPZY)
|
|
---|---|
Pricing data not available |
Open: | $ n/a | Volume: | n/a | |
---|---|---|---|---|
High: | $ n/a | Yield(%) | n/a | |
Low: | $ n/a | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | n/a | |
EPS ($) | n/a | Shares Out: | n/a |
% Price Change (last 4 weeks): | n/a |
---|---|
% Price Change (last 13 weeks): | n/a |
% Price Change (last 26 weeks): | n/a |
% Price Change (last 52 weeks): | n/a |
% Price Change (year to date): | n/a |
Return on Equity (%): | n/a |
---|---|
Return on Assets (%): | n/a |
Return on Invested Capital (%): | n/a |
Gross Profit Margin (%): | n/a |
---|---|
Net Profit Margin (%): | n/a |
Operating Profit Margin (%): | n/a |
|
|
50-day Moving Average: | $n/a |
---|---|
200-day Moving Average: | $n/a |
Avg. Daily Vol. (last 50 days): | n/a |
Avg. Daily Vol. (last 200 days): | n/a |
52-wk high: | $n/a |
52-wk low: | $n/a |
Bid: | $n/a |
Ask: | $n/a |
Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark.
|
Veloxis Pharmaceuticals
Amerika Plads 37 Copenhagen CR 2100 Phone: 45.70.33.33.00 Fax: 45.36.13.03.19 http://www.veloxis.com |
Earnings (1year) ($): | 0.38 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | n/a |
Cash Flow ($): | n/a |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | n/a |
Price/Book (x): | n/a |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | n/a |
---|---|
Current Ratio (x): | n/a |
LT Debt/Equity (x): | n/a |
Total Debt/Equity (x): | n/a |